利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

17 条记录 (耗时 0.018 秒)

    NOVEL BICYCLIC THIAZOLE COMPOUNDS
    4.
    发明公开
    NOVEL BICYCLIC THIAZOLE COMPOUNDS 审中-公开
    NEUARTIGE BICYCLISCHE THIAZOLVERBINDUNGEN

    公开(公告)号：EP2855470A1

    公开(公告)日：2015-04-08

    申请号：EP13729492.2

    申请日：2013-05-22

    申请人： Carna Biosciences, Inc. ,  National Cancer Center

    发明人： SAWA, Masaaki ,  MORIYAMA, Hideki ,  YAMADA, Tesshi ,  SHITASHIGE, Miki ,  KAWASE, Yusuke ,  UNO, Yuko

    IPC分类号： C07D417/12 ,  C07D417/14 ,  C07D277/56 ,  A61K31/427 ,  A61P35/00

    CPC分类号： C07D277/56 ,  C07D417/12 ,  C07D417/14

    摘要： The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R1, R2, R3 and Q are as defined in the specification), or a pharmaceutically acceptable salt thereof.

    摘要翻译： 本发明涉及抑制Traf2-和Nck相互作用激酶（TNIK）的新型双环噻唑化合物，并且因此可用作给予癌症患者的TNIK抑制剂，特别是用于固体癌症患者如结肠直肠癌，胰腺癌， 小细胞肺癌，前列腺癌或乳腺癌。 双环噻唑化合物由下式（I）表示。 （其中R 1，R 2，R 3和Q如说明书中所定义）或其药学上可接受的盐。

    NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE
    7.
    发明公开
    NOVEL 2,6-DIAMINOPYRIMIDINE DERIVATIVE 审中-公开
    中和剂2,6-二氨基嘧啶衍生物

    公开(公告)号：EP3042899A1

    公开(公告)日：2016-07-13

    申请号：EP14842654.7

    申请日：2014-09-01

    申请人： Carna Biosciences, Inc.

    发明人： KAWAHATA, Wataru ,  ASAMI, Tokiko ,  SAWA, Masaaki ,  IRIE, Takayuki

    IPC分类号： C07D401/10 ,  C07D401/14 ,  A61K31/506 ,  A61K31/5377 ,  A61P19/08 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

    CPC分类号： C07D403/14 ,  C07D401/10 ,  C07D401/14

    摘要： To provide a novel 2,6-diaminopyrimidine derivative by the following formula (I):
    A 2,6-diaminopyrimidine derivative is represented by the formula (I):

    wherein
    R 1 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,
    Ar represents a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group,
    Z 1 and Z 2 represent carbon atoms, or either 1 or 2 of the Z 1 and Z 2 represent nitrogen atoms,
    Q is selected from a structure (a) or (b) described below:

    R 2 represents a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted cycloalkyl group,
    R 3 represents a hydrogen atom or a halogen atom,
    Y represents a nitrogen atom or a carbon atom, and
    the bond drawn with a dotted line parallel to a solid line on structure (a) represents either double bond or single bond.

    摘要翻译： 通过下式（I）提供新的2,6-二氨基嘧啶衍生物：2,6-二氨基嘧啶衍生物由式（I）表示：其中R 1表示取代或未取代的低级烷基，或取代或未取代的 未取代的烷氧基，Ar表示取代或未取代的芳基或取代或未取代的杂芳基，Z 1和Z 2表示碳原子，或者1或2的Z 1和Z 2表示氮原子，Q选自 下述结构（a）或（b）：R 2表示取代或未取代的低级烷基或取代或未取代的环烷基，R 3表示氢原子或卤素原子，Y表示氮原子或碳 原子，并且用结构（a）上平行于实线的虚线绘制的键表示双键或单键。

    NOVEL TRIAZINE DERIVATIVE
    10.
    发明公开
    NOVEL TRIAZINE DERIVATIVE 审中-公开
    新的三嗪衍生物

    公开(公告)号：EP2824099A1

    公开(公告)日：2015-01-14

    申请号：EP13758233.4

    申请日：2013-03-07

    申请人： Carna Biosciences, Inc.

    发明人： KAWAHATA, Wataru ,  ASAMI, Tokiko ,  SAWA, Masaaki ,  ASAMITSU, Yuko ,  IRIE, Takayuki ,  MIYAKE, Takahiro ,  KIYOI, Takao

    IPC分类号： C07D251/42 ,  A61K31/53 ,  A61K31/5377 ,  A61P19/00 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/06 ,  A61P43/00

    CPC分类号： C07D513/04 ,  A61K31/53 ,  A61K31/5377 ,  C07D251/18 ,  C07D251/22 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D487/04 ,  C07D495/04

    摘要： To provide a novel triazine derivative represented by the following formula (I):
    A triazine derivative represented by the following formula (I) :

    wherein
    R 1 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, a substituted or unsubstituted heterocyclic fused ring, or a substituted or unsubstituted alkynyl group,
    R 2 represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, or a substituted or unsubstituted alkoxy group,
    R 3 represents a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic ring, or a substituted or unsubstituted heterocyclic fused ring,
    R 4 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, or a halogen atom, and

    R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, or R 1 and R 5 may be combined to form a saturated or unsaturated 5- to 6-membered ring, thereby forming a multiply fused ring,
    or a pharmaceutically acceptable salt thereof.

    摘要翻译： 为了提供由下式（I）表示的新型三嗪衍生物：由下式（I）表示的三嗪衍生物：其中R1表示取代或未取代的芳基，取代或未取代的杂环，取代或未取代的杂环稠合 环或取代或未取代的炔基，R 2表示氢原子，卤素原子，取代或未取代的低级烷基或取代或未取代的烷氧基，R 3表示取代或未取代的芳基，取代或未取代的杂环 环或取代或未取代的杂环稠环，R 4表示氢原子，取代或未取代的低级烷基，取代或未取代的烷氧基，取代或未取代的氨基或卤素原子，R 5表示氢原子 ，取代或未取代的低级烷基，或者R 1和R 5可以结合形成饱和的 或不饱和的5至6元环，由此形成多重稠环或其药学上可接受的盐。